Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hormones and Bone Tissue01:17

Hormones and Bone Tissue

3.5K
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
3.5K
Bone Disorders01:29

Bone Disorders

8.0K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
8.0K
Bone Remodeling01:40

Bone Remodeling

34.4K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
34.4K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

3.9K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.9K
Role of Vitamins in Maintaining Bone Health01:25

Role of Vitamins in Maintaining Bone Health

5.1K
The growth and maintenance of bone are regulated by a combination of nutritional factors, including vitamins, such as vitamin A, B12, C, D, and K.
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
5.1K
Skeleton and Calcium Homeostasis01:21

Skeleton and Calcium Homeostasis

8.5K
Calcium is not only the most abundant mineral in bone but also the most abundant mineral in the human body. Calcium ions are needed for bone mineralization, tooth health, heart rate regulation and strength of contraction, blood coagulation, the contraction of smooth and skeletal muscle cells, and the regulation of nerve impulse conduction. The average calcium level in the blood is about 10 mg/dL. When the body cannot maintain this level, a person will experience hypo or hypercalcemia.
8.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Benefits and harms of antiresorptive therapy in men with non-metastatic prostate cancer on androgen deprivation therapy: A systematic review and meta-analysis of randomized controlled trials.

Metabolism: clinical and experimental·2026
Same author

Intraoperative PTH monitoring: does sampling site or assay generation matter?

Journal of the Endocrine Society·2026
Same author

Pregnancy and Lactation Associated Osteoporosis: A Systematic Review.

Calcified tissue international·2026
Same author

Long-Term Diets and Changes in Body Composition and Bone Mineral Density: A Systematic Review and Meta-analysis.

Nutrition reviews·2026
Same author

Enhancing the Implementation of a high-quality randomized trial in pregnancy.

Research square·2026
Same author

Vitamin D insufficiency in pregnant women from Lebanon: prevalence and key predictors.

Reproductive health·2025

Related Experiment Video

Updated: May 6, 2026

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
11:47

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders

Published on: June 8, 2014

11.1K

Incretin based therapies: bone protective effects.

Marlene Chakhtoura, Sami T Azar1

  • 1Department of Internal Medicine, Division of Endocrinology and Metabolism, American University of Beirut-Medical Center, 3 Dag Hammarskjold Plaza, 8th floor, New York, NY 10017, USA. sazar@aub.edu.lb.

Endocrine, Metabolic & Immune Disorders Drug Targets
|October 22, 2013
PubMed
Summary
This summary is machine-generated.

Type 2 Diabetes Mellitus (T2D) is linked to bone loss and increased fracture risk. Newer diabetes drugs show potential skeletal benefits by aiding bone formation and reducing resorption, but more human data is needed.

More Related Videos

Peptides from Phage Display Library Modulate Gene Expression in Mesenchymal Cells and Potentiate Osteogenesis in Unicortical Bone Defects
07:53

Peptides from Phage Display Library Modulate Gene Expression in Mesenchymal Cells and Potentiate Osteogenesis in Unicortical Bone Defects

Published on: December 10, 2010

21.5K
Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
08:53

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model

Published on: January 1, 2017

8.8K

Related Experiment Videos

Last Updated: May 6, 2026

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
11:47

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders

Published on: June 8, 2014

11.1K
Peptides from Phage Display Library Modulate Gene Expression in Mesenchymal Cells and Potentiate Osteogenesis in Unicortical Bone Defects
07:53

Peptides from Phage Display Library Modulate Gene Expression in Mesenchymal Cells and Potentiate Osteogenesis in Unicortical Bone Defects

Published on: December 10, 2010

21.5K
Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
08:53

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model

Published on: January 1, 2017

8.8K

Area of Science:

  • Endocrinology
  • Bone Biology
  • Metabolic Diseases

Background:

  • Type 2 Diabetes Mellitus (T2D) is increasingly recognized for its detrimental effects on bone health.
  • T2D contributes to bone loss via altered bone matrix, inhibited bone formation, and increased fracture risk.

Purpose of the Study:

  • To explore the skeletal benefits of novel antidiabetic agents.
  • To investigate the mechanisms by which dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 agonists impact bone metabolism.

Main Methods:

  • Review of current literature on T2D and bone health.
  • Analysis of preclinical and clinical data on the skeletal effects of DPP-4 inhibitors and GLP-1 agonists.

Main Results:

  • T2D negatively impacts bone quality and strength.
  • DPP-4 inhibitors and GLP-1 agonists demonstrate potential to improve bone health.
  • These agents may stimulate osteoblasts, inhibit advanced glycation end products, and reduce bone resorption.

Conclusions:

  • Novel antidiabetic agents show promise for mitigating T2D-associated bone loss.
  • Further robust clinical evidence in humans is required to confirm these skeletal benefits and establish definitive conclusions.